Proliferative vitreoretinopathy: modern view on etiology and pathogenesis

Artem'eva O.V.; Samoĭlov A.N.; Zhernakov S.V.

doi:https://doi.org/

Close metadata

Recommended articles:

Features of arterial blood flow velocity characteristics in endothelial dysfunction. Russian Journal of Preventive Medicine. 2024;(12):100-106

Immediate results of medicine Slavinorm treatment in patients with atherosclerotic arteries diseases of the lower extremities. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):102-108

Correlation between endothelial dysfunction and sensorineural hearing loss. Russian Bulletin of Otorhinolaryngology. 2025;(3):13-18

Biomarkers of endothelial dysfunction in assessing degrees of the of coronary artery disease severity and features of the ischemic heart disease clinical course in middle-aged men. Russian Journal of Preventive Medicine. 2025;(6):41-47

Hypertensive disorders of pregnancy as a risk factor for chronic non-communicable diseases. Russian Journal of Preventive Medicine. 2025;(6):114-119

Diagnostic strategies for post-COVID syndrome. Russian Journal of Preventive Medicine. 2025;(6):126-130

Chronic kidney disease and microcirculation disorders. Russian Journal of Preventive Medicine. 2025;(8):123-130

«Metabolic health» and endothelial function in women with polycystic ovary syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):27-34

Abstract:

Studies on etiology and pathogenesis of proliferative vitreoretinopathy are necessitated by the absence of a unified theory, which would provide a clear understanding of causes and mechanisms of the disease. The results of recent investigations allow to consider proliferative vitreoretinopathy as an uncontrollable plastic process caused by certain changes in the retina aimed at survival of its cells under oxidative stress. This approach enables preclinical indication of the process and development of new therapies.

Keywords:

proliferative vitreoretinopathy

macrophage

growth factor

endothelial dysfunction

cytokine

Authors:

Artem'eva O.V.

OOO "VITA", klinika "Kuzliar"

Samoĭlov A.N.

GBOU VPO "Kazanskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava Rossii

Zhernakov S.V.

OOO "VITA", klinika "Kuzliar"

Close metadata

References:

Krivosheina O.I. Kletochnye mekhanizmy razvitiya proliferativnoi vitreoretinopatii (eksperimental'no-klinicheskoe issledovanie): Avtoref. diss. d-ra med. nauk [Cellular mechanisms of development of proliferative vitreoretinopathy (experimental and clinical research): Dr. Diss.(Med. Sci.)]. Tomsk; 2004. 35 p.
Gass J.D.M. Stereoscopic atrlas of macular diseases; diagnosis and treatment. St Louis: Mosby; 1997; 158-165.
Pastor J.C. Proliferative vitreoretinopathy: an overview. Surv. Ophthalmol. 1998; 43: 3-18.
El-Ghrably I.A., Dua H.S., Orr G., Fischer D., Tighe P.J. Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br. J. Ophthalmol. 2001; 85: 461-70.
Machemer R. Proliferative vitreoretinopathy - a personal account of its pathogenesis and treatment. Invest. Ophthalmology. 1988; 29: 1771-1783.
Roth A.M., Foos R.Y. Surface wrinkling retinopathy in eye enucleated at autopsy. Trans. Am. Acad. Ophthalmol. 1971; 75: 1047-1059.
Aylward G.W. Ophthalmology. Chapter 6. 41-Proliferative Vitreoretinopathy 3rd ed. Mosby; 2008.
Newsome D.A., Rodrigues M.M., Machemer R. Human massive periretinal proliferation. In vitro characteristics of cellular components. Arch. Ophthalmol. 1981; 99 (5): 873-880.
Ryan S.J. The pathophysiology of proliferative vitreoretinopathy in its management. Am. J. Ophthalmol. 1985; 100 (1): 188-193.
Sdobnikova S.V., Mazurina N.K., Stolyarenko G.E. Modern approach to treatment of proliferative diabetic retinopathy. Rossiiskii meditsinskii zhurnal. 2002; 3 (3): 99-105. (In Russ.)
Tankovskii V.E., Mizerova O.V. Vasoproliferation in thromboses of retinal veins. In: Materialy I nauchno-prakticheskoi konferentsii "Proliferativnyi sindrom v oftal'mologii" [Proc. of the 1st Scientific and practical conf. "Proliferative syndrome in ophthalmology"]. Moscow: RSMU Publ.; 2000; 20-21. (In Russ.)
Travkin A.G., Romashenko A.D. Proliferative syndrome in ophthalmology. In: Materialy VI nauchno-prakticheskoi konferentsii "Proliferativnyi sindrom v oftal'mologii" [Proc. of the 6th Scientific and practical conf. "Proliferative syndrome in ophthalmology"]. Moscow: RSMU Publ.; 2002; 16-17. (In Russ.)
Sidd Rj., Fine S.L., Owens S.L., Patz A. Idiopathic preretinal gliosis. Am. J. Ophthalmol. 1982; 94: 44-48.
Sandali O., Basli E., Borderie V. Recurrence of an idiopathic vasocentric epiretinal membrane: clinical and surgical particularities. J. Fr. Ophthalmol. 2012; 35: 48.e1-48.e5.
Snead D.R., James S., Snead M.P. Pathological changes in the vitreoretinal junction 1: epiretinal membrane formation. Eye (Lond). 2008; 22 (10): 1310-1317.
Aoyama R. Morphological study on the intraocular proliferative membrane of proliferative diabetic retinopathy and proliferative vitreoretinopathy. Nihon Ganka Gakkai Zasshi. 1990; 94 (4): 383-393.
Zhang X., Barile G., Chang S., Hays A., Pachydaki S., Schiff W., Sparrow J. Apoptosis and cell proliferation in proliferative retinal disorders: PCNA, Ki-67, caspase-3, and PARP expression. Curr. Eye Res. 2005; 30 (5): 395-403.
Pennock S., Kazlauskas A. Vascular Endothelial Growth Factor A Competitively Inhibits Platelet-Derived Growth Factor (PDGF)-Dependent Activation of PDGF Receptor and Subsequent Signaling Events and Cellular Responses. Mol. Cell. Biol. 2012; 32 (10): 1955-1966.
Lin M.L., Li Y.P., Li Z.R., Lin J.X., Zhou X.L., Liang D. Macrophages acquire fibroblast characteristics in a rat model of proliferative vitreoretinopathy. Ophthalmic. Research. 2011; 45 (4): 180-190.
Lei H., Rheaume M.A., Kazlauskas A. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp. Eye Res. 2010; 90 (3): 376-381.
Andrews A., Balciunaite E., Leong F.L., Tallquist M., Soriano P., Refojo M., Kazlauskas A. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 1999; 40 (11): 2683-2689.
Cui J.Z., Chiu A., Maberley D., Ma P., Samad А., Matsubara J.A. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye. 2007; 21 (2): 200-208.
Hinton D.R., He S., Jin M.L., Barron E., Ryan S.J. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye. 2002; 16 (4): 422-428.
Ricker L.J., Dieudonné S.C., Kessels A.G., Rennel E.S., Berendschot T.T., Hendrikse F., Kijlstra A., La Heij E.C. Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Retina. 2012; 32 (1): 54-59.
Lei H., Velez G., Hovland P., Hirose T., Gilbertson D., Kazlauskas A. Growth factors outside the PDGF family drive experimental PVR. Invest. Ophthalmol. Vis. Sci. 2009; 50 (7): 3394-3403.
Dieudonné S.C., La Heij E.C., Diederen R.M.H., Kessels A.G., Liem A.T., Kijlstra A., Hendrikse F. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy. Ophthalmic. Research. 2007; 39 (3): 148-154.
Dieudonné S.C., La Heij E.C., Diederen R., Kessels A.G.H., Liem A.T.A., Kijlstra A., Hendrikse F. High TGF-&Bgr;2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2004; 45 (11): 4113-4118.
Limb G.A., Little B.C., Meager A., Ogilvie J.A., Wolstencroft R.A., Franks W.A. Cytokines in proliferative vitreoretinopathy. Eye (London, England). 1991; 5 (6): 686-693.
Banerjee S., Savant V., Scott R.A.H., Curnow S.J., Wallace G.R., Murray P.I. Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest. Ophthalmol. Vis. Sci. 2007; 48 (5): 2203-2207.
Hui Y., Shi Y., Zhang X., Yang K., Yu C. TNF-alpha, IL-8 and IL-6 in the early inflammatory stage of experimental PVR model induced by macrophages. Chin. J. Ophthalmol. 1999; 35 (2): 140-143.
Asaria R.H.Y., Kon C.H., Bunce C., Sethi C.S., Limb G.A., Khaw P.T., Aylward G.W., Charteris D.G. Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid. Br. J. Ophthalmol. 2004; 88 (11): 1439-1442.
La Heij E.C., Van de Waarenburg M.P.H., Blaauwgeers H.G.T., Kessels A.G., De Vente J., Liem A.T., Steinbusch H., Hendrikse F. Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. Am. J. Ophthalmol. 2002; 134 (3): 367-375.
Mukherjee S., Guidry C. The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Invest. Ophthalmol. Vis. Sci. 2007; 48 (4): 1892-1899.
Liou G.I., Pakalnis V.A., Matragoon S., Baker J., Behzadian M.A., Khalil I., Caldwell R.B., Hunt R.C., Marcus D.M. HGF regulation of RPE proliferation in an IL-1&Bgr;/retinal hole-induced rabbit model of PVR. Molec. Vis. 2002; 8: 494-501.
Elner S.G., Elner V.M., Jaffe G.J., Stuart A., Kunkel S.L., Strieter R.M. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr. Eye Res. 1995; 14 (11): 1045-1053.
Stavros N. Moysidis, Thanos A., Vavvas D.G. Mechanisms of Inflammation in Proliferative Vitreoretinopathy: From Bench to Bedside. Mediators Inflamm. 2012; 2012 (11). Avaible at: http: //dx.doi.org/10.1155/2012/815937
Armstrong D., Augustin A.J., Spengler R., Al-Jada A., Nickola T., Grus F., Koch F. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica. 1998; 212 (6): 410-414.
Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54: 4855-4878.
Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88 (3): 323-331.
Toledo F., Wahl G.M. Regulating the p53 pathway: in vitro hypothe.ses, in vivo verities. Nature Reviews Cancer. 2006; 6 (12): 909-923.
Limb G.A., Alam A., Earley O., Green W., Chignell A.H., Dumonde D.C. Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr. Eye Res. 1994; 13 (11): 791-798.
Abdullaeva E.A., Aliev Kh.D., Rustambekova G.R., Shakhbazova N.A. Variants of clinical pathology course of vitreomacular interface according biomicroscopy and optical coherence tomography. Oftal'mologiya. Azerbaidzhan; 2010; 2: 36-39. (In Russ.)
Topchii I.I. Neutrophils and monocytes at vascular endothelial damage as links of a single pathogenetic chain in development of chronic kidney disease and atherosclerosis. Vnutrennyaya meditsina. 2008; 5-6 (11-12). Available at: http: //www.mif-ua.com/archive/issue-6792/article-6834/bibliography.html. (In Russ.)
Shlyakhto E.V., Moiseeva O.M. Cellular aspects of vascular remodeling in arterial hypertension. Arterial'naya gipertenziya. 2002; 2: 45-49. (In Russ.)
Ivanova E.V., Kachalina G.F., Kasmynina T.A., Kuranova O.I. Present view of proliferative vitreoretinopathy pathogenesis. Oftal'mologiya, PM, T. 2; 2012. Available at: http: //pmarchive.ru/sovremennoe-predstavlenie-o-patogeneze-proliferativnoj-vitreoretinopatii/ (In Russ.)
Kon C.H., Occleston N.L., Aylward G.W., Khaw P.T. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest. Ophthalmol. Vis. Sci. 1999; 40 (3): 705-712.
Koerner F., Merz A., Gloor B., Wagner E. Postoperative retinal fibrosis - a controlled clinical study of systemic steroid therapy. Graefes Arch. Clin. Exp. Ophthalmol. 1982; 219 (6): 268-271.
Lei H., Velez G., Cui J., Samad A., Maberley D., Matsubara J., Kazlauskas A. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am. J. Pathol. 2010; 177 (1): 132-140.
Asaria R.H.Y., Kon C.H., Bunce C., Charteris D.G., Wong D., Khaw P.T. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001; 108 (7): 1179-1183.
Charteris D.G., Aylward G.W., Wong D., Groenewald C., Asaria R.H., Bunce C. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004; 111 (12): 2240-2245.
Wickham L., Bunce C., Wong D., McGurn D., Charteris D.G. Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007; 114 (4): 698-704.
Wiedemann P., Hilgers R.D., Bauer P., Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Am. J. Ophthalmol. 1998;126 (4): 550-559.
Moshetova L.K., Volkov O.A. Present view of the tear fluid, its value in diagnosis. Klinicheskaya oftal'mologiya. 2004; 138 (4): 138-139. (In Russ.)